Clinical Trials Logo

Clinical Trial Details — Status: Recruiting

Administrative data

NCT number NCT03067467
Other study ID # STU 012017-070
Secondary ID
Status Recruiting
Phase
First received
Last updated
Start date June 1, 2019
Est. completion date December 31, 2024

Study information

Verified date March 2024
Source University of Texas Southwestern Medical Center
Contact Jeannie D Baxter, RN
Phone 214-645-2726
Email jeannie.baxter@utsouthwestern.edu
Is FDA regulated No
Health authority
Study type Observational

Clinical Trial Summary

This is a non-randomized, purely observational, feasibility study to detect metabolic changes in patients with brain malignancy using a novel hyperpolarized [1-13C]pyruvate MRSI.


Description:

The aim of this pilot study is to test the hypothesis that patients with brain malignancy present altered [1-13C]lactate and 13C-bicarbonate production from infused hyperpolarized [1-13C]pyruvate in tumor as compared to in normal-appearing brain regions. To achieve this aim investigators will assess metabolic phenotype in cancer patients with brain tumors (n = 20). Total target enrollment will be set at 25 subjects to account for attrition and screening failures. During each imaging session, following localization of the tumor in brain, tissue characteristics and morphological changes will be evaluated with 1H MRI. Then, cerebral metabolism will be assessed utilizing 13C MRSI after an intravenous injection with hyperpolarized [1-13C]pyruvate. Finally, contrast-enhanced 1H MRI will be acquired. The study agent, hyperpolarized [1-13C]pyruvate, will be administered under a Food and Drug Administration (FDA) Investigational New Drug (IND), which was approved on 1/3/2017 (IND# 133229). Preliminary data in human are essential to secure larger scale funding required for clinical studies. The investigators believe the ability to measure such metabolic shifts in vivo could have major significance in assessing the efficacy of multiple anti-tumor therapies currently under development that target reversing the Warburg effect as a means of controlling tumor growth. Brain tumor applications at the Advanced Imaging Research Center, Harold C. Simmons Comprehensive Cancer Center and the Neuro-Oncology Program of the Development of Neurological Surgery at the UT Southwestern Medical Center offer today a unique opportunity to lead globally the translational scientific efforts in this field.


Recruitment information / eligibility

Status Recruiting
Enrollment 25
Est. completion date December 31, 2024
Est. primary completion date December 31, 2024
Accepts healthy volunteers No
Gender All
Age group 18 Years to 70 Years
Eligibility Inclusion Criteria: - Definitive diagnosis of brain tumors by imaging which demonstrates all kinds of brain malignancy, including glioma, meningioma, and brain metastases prior to any chemotherapy or radiation treatment. - 18-70 years of age - Ability to understand and the willingness to sign a written informed consent. - All races and ethnicities will be included; subjects must be able to read and speak the English language. Once the protocol is established, Spanish-speaking participants will be included. - Women of child-bearing potential must agree to use adequate contraception (hormonal or barrier method of birth control; abstinence) prior to study entry and for the duration of study participation. Exclusion Criteria: - Subjects who are receiving any other investigational agents. - Previous or current treatment by radiation or chemotherapy. - Concurrent illness including, but not limited to, ongoing or active infection, uncontrolled chronic diseases such as hypertension, lung disease, liver disease, kidney disease, diabetes, symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmias, or psychiatric illness/social situations that would limit compliance with study requirements. - Subjects who have a history of alcohol abuse or illicit drug use. - Subjects must not be pregnant or nursing due to the potential for congenital abnormalities and the potential of this regimen to harm nursing infants - Subjects who have contraindication to contrast enhanced MRI examination Contraindications to MRI examination include: - Medically unstable - Heart failure - Severe LVOT outflow obstruction - Unstable angina - Child bearing - Lactating - Any contraindication per MRI Screening Form including - Implants contraindicated at 3T, pacemakers - Implantable Cardioverter Defibrillator (ICD) - Claustrophobia - Since each subject may be receiving a gadolinium-based contrast agent intravenously: - eGFR = 30 mL/min/1.73m2 - Sickle cell disease - Hemolytic anemia

Study Design


Related Conditions & MeSH terms


Intervention

Drug:
Hyperpolarized 13C-Pyruvate
Hyperpolarized 13C-pyruvate IV bolus followed by brain MRSI.
Gadolinium
Brain MRI performed with and without gadolinium-based contrast.

Locations

Country Name City State
United States UT Southwestern Medical Center Dallas Texas

Sponsors (1)

Lead Sponsor Collaborator
University of Texas Southwestern Medical Center

Country where clinical trial is conducted

United States, 

Outcome

Type Measure Description Time frame Safety issue
Primary 13C-pyruvate Metabolic Product Ratio Measurement of the ratio of metabolic products, [1-13C]lactate and 13C-bicarbonate, from hyperpolarized [1-13C]pyruvate will be used as an index of metabolic balance between glycolytic pathway and mitochondrial oxidative phosphorylation. Screening (Baseline) and 1 day of Study Visit
See also
  Status Clinical Trial Phase
Recruiting NCT04390906 - A Study of Cognitive Changes in Patients Receiving Brain Radiation
Recruiting NCT05298995 - GD2-CAR T Cells for Pediatric Brain Tumours Phase 1
Completed NCT02599142 - Comparing Immobilisation Shells in Cranial Radiotherapy N/A
Not yet recruiting NCT04113278 - Role of Fibirnogen Like Protein 2 as Aprognostic Factor in High Grade Glioma
Enrolling by invitation NCT06391294 - Neuronal and Network Mechanisms of Electrocortical Stimulation
Active, not recruiting NCT05832450 - Predictive Model to Calculate the Risk of RBC Transfusion in Elective Brain Tumours Resections (TScoreBTR)
Recruiting NCT03213002 - Oral Capecitabine and Temozolomide (CAPTEM) for Newly Diagnosed GBM Phase 1/Phase 2
Recruiting NCT04468919 - Optimizing BCI-FIT: Brain Computer Interface - Functional Implementation Toolkit N/A
Recruiting NCT04742231 - Handheld Dynamometer During Awake Craniotomy Pilot N/A
Recruiting NCT04725032 - Effects of Intravenous Anesthesia and Balanced Anesthesia on Flash Visual Evoked Potentials N/A
Recruiting NCT03542409 - Safety and Feasibility of Preoperative and Intraoperative Image-Guided Resection of Gliomas N/A
Active, not recruiting NCT04165941 - Novel Gamma-Delta (γδ)T Cell Therapy for Treatment of Patients With Newly Diagnosed Glioblastoma Phase 1
Completed NCT03731455 - WISE Cortical Strip for Intraoperative Neurophysiological Monitoring N/A
Suspended NCT05169944 - Magrolimab in Children and Adults With Recurrent or Progressive Malignant Brain Tumors Phase 1